A Study to Evaluate Lutikizumab in Adults with Moderate to Severe Hidradenitis Suppurativa
Official Title
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa
Purpose
The purpose of this study is to evaluate the efficacy of lutikizumab
Could this study be right for you?
-
Subject must have a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least 6 months with lesions in 2 distinct areas
-
Subject must have tried a 12-week (about 3 months) trial of oral antibiotics with inadequate improvement
-
Subject must be in good general health with no history of tuberculosis, HIV, or hepatitis B or C
-
Subject must have no recent history (within 6 months) of significant medical conditions such as a heart attack or stroke
-
Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study